ReviewBMC ophthalmology2025
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a comprehensive literature review of a rare retinal vasculopathy.
Review in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adalimumab in the management of refractory idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and literature review.BMC ophthalmology · 2026Review
- Anti-vascular endothelial growth factor therapies in ophthalmology.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis (IRVAN) syndrome is a rare retinal vasculopathy predominantly affecting young individuals. Characterized by retinal vasculitis, aneurysmal dilations, exudation, and neuroretinitis, IRVAN was initially considered a benign condition. However, emerging evidence highlights its potential for severe vision-threatening complications, emphasizing the need for early diagnosis and intervention. The underlying pathogenesis remains unclear, though inflammatory, vascular, and neuroretinal mechanisms are implicated. While most insights stem from case reports and small cohort studies, IRVAN's clinical presentation varies widely. Affected individuals often experience sudden vision loss, typically due to macular involvement, retinal ischemia, or neovascular complications. Imaging techniques, including fluorescein angiography and optical coherence tomography, are essential for diagnosis, allowing detailed visualization of aneurysmal changes and ischemic progression. Recent discussions have proposed a reclassification of neuroretinitis within the disease framework, suggesting alternative nomenclature emphasizing its vascular pathology. Management strategies focus on reducing ischemia and inflammation. Panretinal laser photocoagulation is the cornerstone of therapy, aiming to mitigate neovascular complications. Corticosteroids, immunosuppressive agents, and biologic therapies play roles in controlling inflammatory components. Anti-Vascular Endothelial Growth Factor (Anti-VEGF) treatments have shown promise, particularly in advanced disease stages. Despite these therapeutic options, IRVAN's unpredictable course necessitates individualized treatment approaches. Although primarily an ocular condition, isolated reports suggest possible systemic associations, including intracranial hypertension and autoimmune markers. Future research should aim to establish standardized diagnostic criteria and therapeutic protocols, enhancing outcomes for affected individuals. This review synthesizes current literature to provide insights into clinical presentation, imaging features, differential diagnoses, and evolving management strategies for this rare disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.